V116517 50-mg tablets
DrugTaken orally twice daily
NCT Number: NCT01688934
The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels of V116517 versus placebo.
Looking for future studies?
Notify Me40 year–80 year
All sexes
Interventional
Phase 2
Genova Clinical Research, Inc., Tucson, Arizona, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol specific inclusion/exclusion criteria may apply.
Taken orally twice daily
Taken orally twice daily
Taken orally twice daily
Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
Time frame: Week 4
Time frame: Week 4
Time frame: Week 4
Time frame: Week 4
Time frame: Week 4
Time frame: Over 4 weeks
Purdue Pharma LP
Industry
A Phase 2, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07571772
Arthritis, Behavior
Erzurum, Yakutiye, Turkey (Türkiye)
View Trial DetailsNCT05869630
Arthritis, Behavior
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT05663996
Arthritis, Joint Diseases
Osmaniye, Turkey (Türkiye)
View Trial DetailsNCT00361504
Arthritis, Back Pain
Mesa, Arizona, United States
View Trial Details